| Literature DB >> 19638317 |
Marcel J de Groot1, Florian Wakenhut, Gavin Whitlock, Ruth Hyland.
Abstract
Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause drug-drug interactions, or is likely to be a victim of inhibition of CYP2D6 by other compounds will be described. Computational models and examples will be given on strategies to design out the CYP2D6 liabilities for both heme-binding compounds and non-heme-binding compounds.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19638317 DOI: 10.1016/j.drudis.2009.07.005
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851